BTK Inhibitor Reduces MS Relapse Rates in Two Phase 3 Trials
Summary
The BTK inhibitor remibrutnib reduces relapse rates and MRI lesion activity compared with teriflunomide in relapsing MS, although its effect on disability progression remains uncertain.
Description from Medscape.
Who is covering this
-
BTK Inhibitor Reduces MS Relapse Rates in Two Phase 3 Trials
The BTK inhibitor remibrutnib reduces relapse rates and MRI lesion activity compared with teriflunomide in relapsing MS, although its effect on disability progression remains uncertain.
